Jenalee Corsello1, Ruth Gerola2, Mercy Babatope2, Semeret Munie2, D Blaine Nease2. 1. Marshall University Joan C. Edwards School of Medicine, General Surgery Residency Program, 1600 Medical Center Drive Suite 2500, Huntington, WV, 25701, USA. corsello@marshall.edu. 2. Marshall University Joan C. Edwards School of Medicine, General Surgery Residency Program, 1600 Medical Center Drive Suite 2500, Huntington, WV, 25701, USA.
Abstract
INTRODUCTION: Obesity is one of the leading public health concerns with over half a million Americans being classified as obese and almost two billion classified as overweight. This has an impact on overall health of the individual, with increased comorbidities and premature death, as well as increased economic cost. This study evaluates the weight loss of patients with limited societal support and resources cared for at a single bariatric center of excellence, The Center for Surgical Weight Control, in Cabell County, West Virginia. METHODS: Retrospective review of patients that have undergone either a Vertical Sleeve Gastrectomy (VSG) or a Roux-en-Y gastric bypass (RNYGB) between the years of 2017 and 2018 At the Center for Surgical Weight Control. Weight loss was evaluated at 6 months, 1 year, and 2 years. RESULTS: There were 290 patients between 2017 and 2018. On average, the VSG group lost 46% of excess body weight (EBW) at 6 months, 57% of EBW at 1 year, and 61% of EBW at 2 years. In the RNYGB group patients lost on average 54% of EBW at 6 months, 65% of EBW at 1 year, and 88% of EBW at 2 years. DISCUSSION: A loss of 5-15% of EBW can improve obesity-related comorbidities. These comorbidities include diabetes, hypertension, hyperlipidemia, gastroesophageal reflux disease, and obstructive sleep apnea. Improvement in these comorbidities not only benefits each patient individually, but will also help improve the effects on society as a whole. CONCLUSION: Obesity is a debilitating and deadly disease, thus makes it very important to address in order to reduce burden on both patients and society as a whole. There is an expected amount of weight loss a patient should have depending on the type of surgery they undergo. Our patients were successful at meeting and exceeding the expected percentage of EBW loss after both VSG and RNYGB.
INTRODUCTION: Obesity is one of the leading public health concerns with over half a million Americans being classified as obese and almost two billion classified as overweight. This has an impact on overall health of the individual, with increased comorbidities and premature death, as well as increased economic cost. This study evaluates the weight loss of patients with limited societal support and resources cared for at a single bariatric center of excellence, The Center for Surgical Weight Control, in Cabell County, West Virginia. METHODS: Retrospective review of patients that have undergone either a Vertical Sleeve Gastrectomy (VSG) or a Roux-en-Y gastric bypass (RNYGB) between the years of 2017 and 2018 At the Center for Surgical Weight Control. Weight loss was evaluated at 6 months, 1 year, and 2 years. RESULTS: There were 290 patients between 2017 and 2018. On average, the VSG group lost 46% of excess body weight (EBW) at 6 months, 57% of EBW at 1 year, and 61% of EBW at 2 years. In the RNYGB group patients lost on average 54% of EBW at 6 months, 65% of EBW at 1 year, and 88% of EBW at 2 years. DISCUSSION: A loss of 5-15% of EBW can improve obesity-related comorbidities. These comorbidities include diabetes, hypertension, hyperlipidemia, gastroesophageal reflux disease, and obstructive sleep apnea. Improvement in these comorbidities not only benefits each patient individually, but will also help improve the effects on society as a whole. CONCLUSION: Obesity is a debilitating and deadly disease, thus makes it very important to address in order to reduce burden on both patients and society as a whole. There is an expected amount of weight loss a patient should have depending on the type of surgery they undergo. Our patients were successful at meeting and exceeding the expected percentage of EBW loss after both VSG and RNYGB.
Authors: Jonathan D Douros; Jingjing Niu; Sophia Sdao; Trillian Gregg; Kelsey Fisher-Wellman; Manish Bharadwaj; Anthony Molina; Ramamani Arumugam; MacKenzie Martin; Enrico Petretto; Matthew J Merrins; Mark A Herman; Jenny Tong; Jonathan Campbell; David D'Alessio Journal: JCI Insight Date: 2019-03-21
Authors: Bethany P Cummings; Ahmed Bettaieb; James L Graham; Kimber L Stanhope; Mark Kowala; Fawaz G Haj; Michael L Chouinard; Peter J Havel Journal: Endocrinology Date: 2012-06-19 Impact factor: 4.736
Authors: Hilary E Wilson-Pérez; Adam P Chambers; Karen K Ryan; Bailing Li; Darleen A Sandoval; Doris Stoffers; Daniel J Drucker; Diego Pérez-Tilve; Randy J Seeley Journal: Diabetes Date: 2013-02-22 Impact factor: 9.461
Authors: Anne K McGavigan; Zachariah M Henseler; Darline Garibay; Scott D Butler; Sisitha Jayasinghe; Ruth E Ley; Robin L Davisson; Bethany P Cummings Journal: Dis Model Mech Date: 2017-01-12 Impact factor: 5.758
Authors: Oddrun Anita Gudbrandsen; Simon Nitter Dankel; Lillian Skumsnes; Tone Nygaard Flølo; Oddry Henriette Folkestad; Hans Jørgen Nielsen; Villy Våge; Arne Christian Mohn; Bjørn Gunnar Nedrebø; Jørn V Sagen; Johan Fernø; Gunnar Mellgren Journal: Sci Rep Date: 2019-10-15 Impact factor: 4.379
Authors: Rahman G Barry; Farzad A Amiri; Todd W Gress; D Blaine Nease; Timothy D Canterbury Journal: Medicine (Baltimore) Date: 2017-09 Impact factor: 1.889